Genomics, Signaling, and Treatment of Waldenstrom's MacroglobulinemiaWaldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...

Latest Bing Center News

29th Annual IWMF Educational Forum

29th Annual IWMF Educational Forum

Join us May 3-5, 2024, at the Hyatt Regency in Renton, Washington for the 2024 Ed Forum. Renton, Washington is a lively suburb of Seattle and nestled on the southeast shore of Lake Washington. The Hyatt Regency and Lake Washington provide a picturesque backdrop to support education and engagement for the WM community.

Read more..

A Cure in Sight for Waldenstrom's Macroglobulinemia

A Cure in Sight for Waldenstrom's Macroglobulinemia

Dr. Steven Treon explains how recent advances in understanding the genomics and biology of Waldenstrom's macroglobulinemia make him hopeful and optimistic about a cure.

Read more..

Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses preliminary data from a phase 2 study (NCT05065554) of acalabrutinib (Calquence) plus rituximab (Rituxan) in patients with Waldenström’s Macroglobulinemia or IgM symptomatic anti-myelin associated glycoprotein (MAG)–mediated peripheral neuropathy.

Read more..

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses the efficacy of treatment with iopofosine I 131 (previously CLR 131) in patients with Waldenström macroglobulinemia.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..

In Memoriam of Dr. Enrica Morra

In Memoriam of Dr. Enrica Morra

Dear Members of the Waldenstrom’s Macroglobulinemia Community: I wanted to share with you the sad news that our colleague and friend, Dr. Enrica Morra recently passed away. Dr. Morra was the Co-Chair of 6th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) which was held in Venice, Italy (2010), and a recipient of the Jan Gosta Waldenstrom Award for Lifetime Contributions to Waldenstrom’s Macroglobulinemia at the 8th IWWM in London, UK (2014).

Read more..

ASH-2023 Posters Presented

ASH-2023 Posters Presented

The following posters were presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

ASH 2023 - Bing Center Abstracts to be Presented

ASH 2023 - Bing Center Abstracts to be Presented

The following abstracts represent the research that will be presented by the Bing Center at the ASH 2023 meeting, December 9-12, 2023 in San Diego. For more information about the ASH 2023 meeting, please visit https://www.hematology.org/meetings/annual-meeting.

Read more..

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom: Reaching the Relapsed Refractory Stage

Waldenstrom Macroglobulinemia (WM) is not curable, which means most patients will either reach the relapsed or refractory stage at some point in their journey. Patient Power spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what reaching these stages mean for WM patients.

Read more..

Waldenstrom Macroglobulinemia: Who Gets What and When?

Waldenstrom Macroglobulinemia: Who Gets What and When?

As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.

Read more..